Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu-Tamrada
- Development stage
- Preclinical
- Lead developer
- Ironfist Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Lu-Tamrada (also known as 177Lu-Tamrada) is a first-in-class nanomedicine radiopharmaceutical developed by Ironfist Therapeutics (a sister company of Programmable Medicine) for the treatment of solid tumors. It consists of a hydroxyl polyamidoamine (PAMAM) dendrimer nanomedicine conjugated to a DOTA chelator that captures the beta-emitting radioisotope lutetium-177 (177Lu). Unlike conventional radiopharmaceuticals that target tumor-specific antigens, Lu-Tamrada is tumor-agnostic and selectively targets tumor-associated macrophages (TAMs) in the tumor microenvironment without requiring a targeting ligand. Upon uptake by TAMs via receptor-independent endocytosis, the drug is retained intracellularly, delivering localized radiation that ablates immunosuppressive TAMs, halts tumor growth, and re-sensitizes the tumor microenvironment to immune checkpoint inhibitors.
- Brand names
- Tamrada
- Other names
- 177Lu-Tamrada[177Lu]Lu-Tamradalutetium (177Lu) Tamradalutetium Lu 177 Tamradalutetium-177 Tamradalutetium177 Tamradalutetium 177 Tamrada
Beyond the preview
Go deeper on Lu-Tamrada.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu-Tamrada.